SCHEMBL2480908

SCHEMBL2480908

N#CCC(=O)N1CCN(c2ccc(Nc3cc(NCc4c(F)cccc4F)c(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 7/20 0.53
SYK P43405 6/20 0.46
JAK3 P52333 7/20 0.46
JAK2 O60674 3/20 0.46
JAK1 P23458 3/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
TYK2 P29597 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2479856 0.92 STAT6 (0.54) STAT6SYKJAK3JAK2JAK1
SCHEMBL2484926 0.88 STAT6 (0.53) STAT6SYKJAK3JAK2JAK1
SCHEMBL2479247 0.88 JAK3 (0.62) STAT6SYKJAK3JAK2JAK1
SCHEMBL2482754 0.88 JAK3 (0.55) STAT6SYKJAK3JAK2JAK1
SCHEMBL12301613 0.87 STAT6 (0.53) STAT6SYKJAK3JAK2JAK1
SCHEMBL12322720 0.86 STAT6 (0.60) STAT6SYKJAK3JAK2JAK1
SCHEMBL2480814 0.86 STAT6 (0.55) STAT6SYKJAK3JAK2JAK1
SCHEMBL12322726 0.86 STAT6 (0.58) STAT6SYKJAK3JAK2JAK1
SCHEMBL2482105 0.85 JAK3 (0.58) STAT6SYKJAK3JAK2JAK1
SCHEMBL2480596 0.85 STAT6 (0.71) STAT6JAK3JAK2JAK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US claimed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP claimed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US claimed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA STAT6 8/4885SYK 137/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.